Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Contribution of Caspase-8 Genotypes to Colorectal Cancer Risk in Taiwan

MING-HSIEN WU, YI-WEN HUNG, CHI-LI GONG, CHI-CHANG CHAO, TE-CHENG YUEH, SHOU-CHENG WANG, YI-LIANG LAI, SHIH-WEI HSU, CHUN-KAI FU, YUN-CHI WANG, TAO-WEI KE, WEN-SHIN CHANG, CHIA-WEN TSAI and DA-TIAN BAU
Anticancer Research June 2019, 39 (6) 2791-2797; DOI: https://doi.org/10.21873/anticanres.13406
MING-HSIEN WU
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
2Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan, R.O.C.
3Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
4National Defense Medical Center, Taipei, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YI-WEN HUNG
5Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHI-LI GONG
6Department of Physiology, China Medical University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHI-CHANG CHAO
7Institute of Neurosciences, National Chengchi University, Taipei, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TE-CHENG YUEH
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
2Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan, R.O.C.
3Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
4National Defense Medical Center, Taipei, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHOU-CHENG WANG
3Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
4National Defense Medical Center, Taipei, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YI-LIANG LAI
3Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
4National Defense Medical Center, Taipei, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHIH-WEI HSU
3Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
4National Defense Medical Center, Taipei, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHUN-KAI FU
3Taichung Armed Forces General Hospital, Taichung, Taiwan, R.O.C.
4National Defense Medical Center, Taipei, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YUN-CHI WANG
2Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAO-WEI KE
2Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WEN-SHIN CHANG
2Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
CHIA-WEN TSAI
2Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
DA-TIAN BAU
1Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan, R.O.C.
2Terry Fox Cancer Research Laboratory, Translational Medicine Research Center, China Medical University Hospital, Taichung, Taiwan, R.O.C.
8Department of Bioinformatics and Medical Engineering, Asia University, Taichung, Taiwan, R.O.C.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: datian@mail.cmuh.org.tw artbau2@gmail.com
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: The aim of this study was to examine the role of caspase-8 rs3834129 polymorphism on colorectal cancer (CRC) risk in Taiwanese CRC patients and healthy controls. Materials and Methods: The caspase-8 rs3834129 (-652 6N insertion/deletion) polymorphic genotypes were analyzed in 362 patients with CRC and the same number of age- and gender-matched healthy subjects. The interaction of caspase-8 rs3834129 genotypes with personal behaviors and clinicopathological features were also examined. Results: The percentage of variants ID and DD for caspase-8 rs3834129 genotype were 37.6 and 5.8% in CRC group and 39.0 and 6.6% in the control group, respectively (p for trend=0.7987). The allelic frequency distribution analysis showed that caspase-8 rs3834129 D allele conferred a non-significant lower susceptibility for CRC compared with I allele (OR=0.92, 95%CI=0.74-1.20, p=0.5063). There was no obvious link between caspase-8 rs3834129 genotype and CRC risk among ever-smokers, non-smokers, non-alcohol drinkers or alcohol drinkers. No statistically significant correlation was observed between caspase-8 rs3834129 genotypic distribution and age, gender, tumor size, location or metastasis status. Conclusion: Overall, caspase-8 rs3834129 genotypes may not serve as predictors for CRC risk or prognosis.

  • Case–control study
  • caspase-8
  • colorectal cancer
  • genotype
  • polymorphism
  • Taiwan

Colorectal cancer (CRC) is the third most prevalent type and the fourth most death-causing cancer worldwide (1, 2). In Taiwan, the incidence and mortality of CRC has been ranked as the first and third cancer among the common types of cancer for many years (3), and the extremely high incidence of CRC has been closely associated with the modern dietary habits of the Western world and the rapid decrease in the consumption of dietary fiber or grain-derived foods. However, the definitive mechanisms of CRC carcinogenesis remain largely unknown. Mounting evidence has suggested that CRC is the result of the interaction among individual genomic and environmental factors, which are waiting to be revealed in the era of precise medicine (4-6). This hypothesis is supported by epidemiological studies, which attributed indirect evidence for the involvement of specific lifestyle and environmental factors in the etiology of more than 85% of CRC cases, particularly meat consumption, cigarette smoking, and exposure to carcinogenic aromatic amines, such as arylamines and heterocyclic amines (7, 8). In addition, 15-20% of CRC cases have a history of familial cancer that have led molecular epidemiologists to search for genomic susceptibility factors that can serve as cancer predictors (9-11). In Taiwan, although several biomarkers for early detection of CRC have been revealed and published during the past decade (12-18), their phenotype and value in clinical practice is not yet known.

Programmed cell death, also named apoptosis, is an essential mechanism to maintain proper cellular growth rate in a stable population (19). It has been reported that aberrant apoptotic pathway is closely associated with tumorigenesis in CRC (20, 21). Caspases are recognized as a family of regulative and executive proteins in the typical apoptosis processes (22). Among them, caspase-8 is one of the most important members of the caspase family of proteins playing an important role in apoptosis (20, 23), especially in mediating the extrinsic apoptotic pathway (24). The protein is encoded by the caspase-8 (also known as CASP8) gene which has 11 exons and is located on chromosome 2q33 q34. Several caspase-8 gene SNPs have been identified to be associated with the risk of various types of cancer (25-28). Among them, the caspase-8 rs3834129 (-652, 6N ins/del) polymorphism, a six-nucleotide insertion (I)/deletion (D) variant, has been functionally shown to lead to the down-regulation of the mRNA of caspase-8 (29). Caspase-8 SNPs are reported to be genomic markers for prediction of the personal risk for several types of cancer, including neuroblastoma (26), bladder cancer (30) and breast cancer (27). Among them, caspase-8 rs3834129 is the most investigated SNP on caspase-8. Epidemiological studies have extensively examined the association between caspase-8 rs3834129 polymorphism and CRC risk, with discrepant results. Therefore, the current case–control study, aimed to investigate the distribution of genotypes of caspase-8 rs3834129 polymorphism, evaluate its association with CRC risk in a Taiwanese population, and discuss concisely the differences and similarities among this and other studies.

Materials and Methods

Collected population. The investigated population was composed of 724 individuals, including 362 patients diagnosed with CRC and the same number of control subjects. The 362 patients diagnosed with CRC were recruited at the outpatient clinics of general surgery at the China Medical University Hospital by the surgical teams under the supervision of LB Jeng and MD Yang during the period between 2002 and 2008. The clinical characteristics for the investigated patients, including their histological details, were all identified and recorded by the well-trained surgeons (13, 18, 31). Well-matched for age (no different than 5 years), gender (most of them were the same) and some specific habits (such as smoking and alcohol drinking), 362 non-cancer healthy volunteers were selected as controls after initial random sampling from the Health Examination Cohort of the Hospital with the help of colleagues at the Department of Family Medicine. The exclusion criteria of the controls included previous malignancy, metastasized cancer from other or unknown origin and any familial or genetic diseases. All the 724 recruited participants completed a self-administered questionnaire and provided a 5-ml sample of peripheral blood for genotyping. This study has been approved by the Institutional Review Board of the China Medical University Hospital (IRB project identification coding number: DMR99-IRB-108) and written informed consents were obtained from all the participants with the help of Tissue-Bank of China Medical University Hospital. The selective demographic information for all the 724 participants in this study is summarized in Table I.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Summary of selected data of the 362 patients with colorectal cancer and 362 matched non-cancer healthy controls.

Genotyping conditions for caspase-8 rs3834129. Genomic DNA was extracted within 12 h after getting the blood from the peripheral blood leukocytes using the QIAamp Blood Mini Kit (Blossom, Taipei, Taiwan, ROC), stored long-term at −80°C, then diluted and aliquoted for caspase-8 rs3834129 genotyping as a working stock at −20°C as per our routine practice (12, 14). The primer pairs and the selection of restriction enzymes used for caspase-8 rs3834129 genotyping are listed in Table II. The polymerase chain reaction (PCR) cycling conditions were: one cycle at 94°C for 5 min; 35 cycles at 94°C for 30 sec, 59°C for 30 sec and 72°C for 30 sec, and a final extension at 72°C for 10 min. After PCR, the SNP-containing DNA amplicons were subjected to overnight digestion by restriction endonucleases. Following enzyme digestion, each sample was immediately subject to 3% agarose gel electrophoresis. All the genotypic processing was repeated by two well-trained researchers independently and blindly, and their results were 100% concordant to each other. In addition, the success rate of PCR-restrictive fragment length polymorphism (RFLP) was 100%, and the genotypes of 5% of the participants in both the control and patient groups were randomly selected and subject to PCR direct sequencing (Genomics BioSci & Tech Co. There was 100% concordance in the results obtained by direct sequencing and PCR-RFLP.

Statistical analysis. The Student's t-test was used for the comparison of the continuous variables such as age among the CRC cases and controls. The Pearson's Chi-square was used to compare the distribution of the caspase-8 rs3834129 genotypes among the investigated subjects. The associations between caspase-8 rs3834129 genotypes and CRC risk were estimated with the indexes of computing odds ratios (ORs) and their 95% confidence intervals (CIs) using logistic regression analysis. Similar to typical cancer genomic studies, any difference between the two groups at p<0.05 was identified as statistically significant.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Primers, and DNA products after PCR and after enzyme digestion for caspase-8 rs3834129.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Distributions of caspase-8 rs3834129 genotypic frequencies among the patients with colorectal cancer and healthy controls.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table IV.

Allelic frequencies for caspase-8 rs3834129 polymorphisms among the patients with colorectal cancer and healthy controls.

Results

The recording and comparisons of the selected demographic characteristics, including age and gender for the 724 subjects, including 362 patients with CRC and 362 non-cancer healthy controls, are summarized Table I. In addition, the tumor size, location, and lymph node metastasis status of the 362 CRC patients are concisely summarized in Table I. Since the strategies of frequency matching were applied for age, gender and habits in recruiting the 362 non-cancer healthy individuals as controls, there was no difference in respect to the distributions of age and gender between the two groups (p=0.8654 and 0.6525, respectively) (Table I). Also, there was no difference in respect to the distributions of smoking and alcohol drinking status between the control and case groups (data not shown).

The distributions of the caspase-8 rs3834129 genotypes among the 362 non-cancer healthy controls and the 362 patients with CRC are presented and analyzed in Table III. The genotypes of caspase-8 rs3834129 were not differently distributed between the case and control groups (p for trend=0.7987) (Table III). In detail, the caspase-8 rs3834129 heterozygous and homozygous variant ID and DD genotypes were not associated with altered CRC risk compared with the wild-type II genotype (adjusted OR=0.94 and 0.88, 95%CI=0.71-1.23 and 0.49-1.46, p=0.6270 and 0.5818, respectively). In addition, in the dominant model, there was no significant association between D allele carriers (ID+DD) of caspase-8 rs3834129 and CRC risk compared with the II wild-type genotype (adjusted OR=0.90, 95%CI=0.62-1.28, p=0.5496).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table V.

Odds ratios for association of caspase-8 rs3834129 genotype with colorectal cancer after stratification by smoking status.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table VI.

Odds ratios for caspase-8 rs3834129 genotype and colorectal cancer after stratification by alcohol drinking status.

In order to confirm the highlight findings in Table III, analysis of allelic frequency distributions for caspase-8 rs3834129 was also conducted and the results are presented in Table IV. Supporting the conclusion that the genotype of caspase-8 rs3834129 is not associated with CRC risk, the frequency of variant allele D was 24.6% in the case group, slightly but non-significantly lower than that of 26.1% in the control group (adjusted OR=0.92, 95%CI=0.74-1.20, p=0.5063) (Table IV).

Smoking and alcohol drinking habits are well-known risk factors for CRC in Taiwan. Thus, the interactions between the genotypes of caspase-8 rs3834129 and personal cigarette smoking and alcohol drinking behaviors of Taiwanese were examined, and the results are presented in Tables V and VI. Firstly, among non-smokers, people with ID and DD genotypes at caspase-8 rs3834129 were at 0.90- and 0.83-fold odds of having CRC (95%CI=0.63-1.28 and 0.42-1.64, p=0.5677 and 0.5881) (Table V, left panel). After adjusting for confounding factors including age, gender and alcohol drinking status, the statistical results still were maintained at a non-significant level for ID and DD genotypes (Table V, left panel). Similarly, a non-significant effect was found among the non-smokers (Table V, right panel). Secondly, among non-alcohol drinkers and alcohol drinkers, those with ID and DD genotypes at caspase-8 rs3834129 did not have a significantly increased risk of having CRC (Table VI).

The correlations between genotypes of caspase-8 rs3834129 and clinicopathological features of 362 patients with CRC were further stratified, analyzed and presented in Table VII. No statistically significant correlation was observed between caspase-8 rs3834129 genotypic distributions and age, gender, tumor size, location or metastasis status (all p>0.05) (Table VII).

Discussion

Caspase-8 belongs to a family of cysteine proteases, which play critical roles in the regulation of apoptosis and cytokine processing (32). As originally identified, caspase-8 plays a role as an initiator of both the extrinsic and the intrinsic apoptotic pathway after activation by Fas-FasL ligands (33, 34). Further, activated caspase-8 may team-up with initiator caspase-10, contributing to the formation of death inducing signaling complex and subsequently the activation the downstream effector caspases to execute the overall apoptosis (35). Among caspase-8 SNPs, rs3834129 is the most investigated. The first case-control study was conducted by Sun and his colleagues in 2007 to examine the contribution of caspase-8 rs3834129 to several types of cancer (36). They found that the D allele at caspase-8 rs3834129 was associated with a decreased susceptibility to lung, colorectal, esophageal, breast, cervical and gastric cancer among 4995 cases and 4972 controls. Further studies have indicated that caspase-8 rs3834129 genotypes might be associated with a susceptibility to cancers such as melanoma (25), brain tumor (26), breast cancer (27) and kidney cancer (28). Sun and his colleagues have also reported that the deletion genotype at caspase-8 rs3834129 destroys a stimulatory protein 1 binding element in the promoter regulatory region, which may cause decreased CASP8 transcription and eventually reduced apoptosis of antitumor T lymphocytes (36).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table VII.

Correlation between caspase-8 rs3834129 genotype and clinicopathological features of 362 patients with colorectal cancer.

There were several reports examining the contribution of caspase-8 rs3834129 in CRC risk in other populations. A multi-centric study that included 6,733 CRC cases and 7,576 controls recruited from Spain, Italy, USA, England, Czech Republic and the Netherlands has indicated that rs3834129 was not associated with CRC risk (37). This is consistent with the study conducted by Xiao MS et al. which included 305 CRC patients and 342 healthy Chinese controls (38). In order to clarify the role of caspase-8 rs3834129 polymorphism on the risk of CRC, Ying and his colleagues have performed a meta-analysis and concluded that caspase-8 rs3834129 polymorphism was not associated with CRC risk (39). In agreement, the present study, indicated that ID or DD genotypes at caspase-8 rs3834129 are not significantly associated with increased risk of CRC in this Taiwanese population (Table II). Therefore, the direct effect of caspase-8 rs3834129 on carcinogenesis is still controversial and needs further investigation.

Long-term smoking habit has been reported as a risk factor for CRC (40), thus the interaction of caspase-8 rs3834129 genotype and smoking on CRC risk was examined. Among both smokers and non-smokers, variant genotypes at caspase-8 rs3834129 were not associated with altered risk of CRC in Taiwanese (Table V). Similarly, the variant genotypes at caspase-8 rs3834129 were not associated with altered risk of CRC among non-alcohol drinkers or drinkers in Taiwanese (Table VI). In addition, no interaction was found between caspase-8 rs3834129 genotype and age or gender on CRC risk. Regarding tumor size, location and lymph node metastasis, no determinant effect of caspase-8 rs3834129 on CRC was found in the patients investigated (Table VII). These findings also need to be validated by further studies in additional and larger populations.

In conclusion, solid evidence was provided within a moderate and representative population showing that caspase-8 rs3834129 was not associated with increased CRC risk in a Taiwanese population. Additionally, the stratified analyses indicated that smokers and alcohol drinkers do not bear additional risk for CRC. Moreover, caspase-8 rs3834129 variant genotypes were not found to be predictors of poorer prognosis. Further validation in large population-based studies in different ethnicities are urgently encouraged and needed.

Acknowledgements

The Authors would like to thank the personnel of the Tissue-Bank of China Medical University Hospital for their excellent technical assistance including all, doctors, nurses and colleagues. The excellent technical expertise and efforts from Yu-Shih Wang, Huai-Mei Hsu and Hsin-Ting Li are also appreciated. This study was supported mainly by the Taichung Armed Forces General Hospital (107A21) to Dr. Wu and Taichung Veterans General Hospital (TCVGH-1077304B) to Dr. Hung. The statistician Cheng-Li Lin who was supported with a research grant from Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW108-TDU-B-212-133004) is highly appreciated.

Footnotes

  • ↵* These Authors contributed equally to this study.

  • Authors' Contributions

    Research Design: Wu MH and Hung YW; Patient and Questionnaire Summarize: Yueh TC, Wang SC, Lai YL and Ke TW; Experiment Performance: Chao CC, Wang YC and Chang WS; Statistical Analysis: Hsu SW, Fu CK; Manuscript Writing: Tsai CW, Gong CL and Bau DT; Reviewing and Revising: Bau DT, Chang WS and Tsai CW

  • Conflicts of Interest

    The Authors declare no conflict of interest in regard to this study.

  • Received April 15, 2019.
  • Revision received April 30, 2019.
  • Accepted May 2, 2019.
  • Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Siegel RL,
    2. Miller KD,
    3. Fedewa SA,
    4. Ahnen DJ,
    5. Meester RGS,
    6. Barzi A,
    7. Jemal A
    : Colorectal cancer statistics, 2017. CA Cancer J Clin 67: 177-193, 2017. PMID: 28248415. DOI: 10.3322/caac.21395
    OpenUrlCrossRefPubMed
  2. ↵
    1. Bray F,
    2. Ferlay J,
    3. Soerjomataram I,
    4. Siegel RL,
    5. Torre LA,
    6. Jemal A
    : Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68: 394-424, 2018. PMID: 30207593. DOI: 10.3322/caac.21492
    OpenUrlCrossRefPubMed
  3. ↵
    https://www.hpa.gov.tw/Pages/List.aspx?nodeid=269, from Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence.
  4. ↵
    1. Obuch JC,
    2. Ahnen DJ
    : Colorectal Cancer: Genetics is Changing Everything. Gastroenterol Clin North Am 45: 459-476, 2016. PMID: 27546843. DOI: 10.1016/j.gtc.2016.04.005
    OpenUrlCrossRefPubMed
    1. Lichtenstein P,
    2. Holm NV,
    3. Verkasalo PK,
    4. Iliadou A,
    5. Kaprio J,
    6. Koskenvuo M,
    7. Pukkala E,
    8. Skytthe A,
    9. Hemminki K
    : Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343: 78-85, 2000. PMID: 10891514. DOI: 10.1056/NEJM200007133430201
    OpenUrlCrossRefPubMed
  5. ↵
    1. Douaiher J,
    2. Ravipati A,
    3. Grams B,
    4. Chowdhury S,
    5. Alatise O,
    6. Are C
    : Colorectal cancer-global burden, trends, and geographical variations. J Surg Oncol 115: 619-630, 2017. PMID: 28194798. DOI: 10.1002/jso.24578
    OpenUrl
  6. ↵
    1. Nagini S
    : Carcinoma of the stomach: A review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 4: 156-169, 2012. PMID: 22844547. DOI: 10.4251/wjgo.v4.i7.156
    OpenUrlCrossRefPubMed
  7. ↵
    1. Jayasurya R,
    2. Sathyan KM,
    3. Lakshminarayanan K,
    4. Abraham T,
    5. Nalinakumari KR,
    6. Abraham EK,
    7. Nair MK,
    8. Kannan S
    : Phenotypic alterations in Rb pathway have more prognostic influence than p53 pathway proteins in oral carcinoma. Mod Pathol 18: 1056-1066, 2005. PMID: 15731778. DOI: 10.1038/modpathol.3800387
    OpenUrlCrossRefPubMed
  8. ↵
    1. Butterworth AS,
    2. Higgins JP,
    3. Pharoah P
    : Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 42: 216-227, 2006. PMID: 16338133. DOI: 10.1016/j.ejca.2005.09.023
    OpenUrlCrossRefPubMed
    1. Houlston RS,
    2. Tomlinson IP
    : Polymorphisms and colorectal tumor risk. Gastroenterology 121: 282-301, 2001. PMID: 11487538.
    OpenUrlCrossRefPubMed
  9. ↵
    1. Rasool S,
    2. Rasool V,
    3. Naqvi T,
    4. Ganai BA,
    5. Shah BA
    : Genetic unraveling of colorectal cancer. Tumour Biol 35: 5067-5082, 2014. PMID: 24573608. DOI: 10.1007/s13277-014-1713-7
    OpenUrlCrossRefPubMed
  10. ↵
    1. Lin KM,
    2. Yang MD,
    3. Tsai CW,
    4. Chang WS,
    5. Hsiao CL,
    6. Jeng LB,
    7. Yueh TC,
    8. Lee MC,
    9. Bau DT
    : The role of MTHFR genotype in colorectal cancer susceptibility in Taiwan. Anticancer Res 38: 2001-2006, 2018. PMID: 29599316. DOI: 10.21873/anticanres. 12438
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Yueh TC,
    2. Chou AK,
    3. Gong CL,
    4. Fu CK,
    5. Pei JS,
    6. Wu MH,
    7. Tsai CW,
    8. Chang WS,
    9. Hsiao CL,
    10. Yen ST,
    11. Li HT,
    12. Bau DT
    : The contribution of excision repair cross-complementing group 1 genotypes to colorectal cancer susceptibility in Taiwan. Anticancer Res 37: 2307-2313, 2017. PMID: 28476796. DOI: 10.21873/anticanres.11568
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Shih LC,
    2. Li CH,
    3. Sun KT,
    4. Chen LY,
    5. Hsu CL,
    6. Hung YW,
    7. Wu CN,
    8. Hsia TC,
    9. Shen TC,
    10. Chang WS,
    11. Shih TC,
    12. Tsai CW,
    13. Bau DT
    : Association of matrix metalloproteinase-7 genotypes to the risk of oral cancer in Taiwan. Anticancer Res 38: 2087-2092, 2018. PMID: 29599326. DOI: 10.21873/anticanres.12448
    OpenUrlAbstract/FREE Full Text
    1. Huang CY,
    2. Tsai CW,
    3. Hsu CM,
    4. Chang WS,
    5. Shui HA,
    6. Bau DT
    : The significant association of CCND1 genotypes with colorectal cancer in Taiwan. Tumour Biol 36: 6533-6540, 2015. PMID: 25809706. DOI: 10.1007/s13277-015-3347-9
    OpenUrlPubMed
    1. Yang MD,
    2. Tsai CW,
    3. Chang WS,
    4. Tsou YA,
    5. Wu CN,
    6. Bau DT
    : Predictive role of XRCC5/XRCC6 genotypes in digestive system cancers. World J Gastrointest Oncol 3: 175-181, 2011. PMID: 22224172. DOI: 10.4251/wjgo.v3.i12.175
    OpenUrlCrossRefPubMed
    1. Yang MD,
    2. Tsai RY,
    3. Liu CS,
    4. Chang CH,
    5. Wang HC,
    6. Tsou YA,
    7. Wang CH,
    8. Lin CC,
    9. Shyue SK,
    10. Bau DT
    : Association of Caveolin-1 polymorphisms with colorectal cancer susceptibility in Taiwan. World J Gastrointest Oncol 2: 326-331, 2010. PMID: 21160894. DOI: 10.4251/wjgo.v2.i8.326
    OpenUrlPubMed
  13. ↵
    1. Yueh TC,
    2. Hung YW,
    3. Shih TC,
    4. Wu CN,
    5. Wang SC,
    6. Lai YL,
    7. Hsu SW,
    8. Wu MH,
    9. Fu CK,
    10. Wang YC,
    11. Ke TW,
    12. Chang WS,
    13. Tsai CW,
    14. Bau DT
    : Contribution of murine double minute 2 genotypes to colorectal cancer risk in Taiwan. Cancer Genomics Proteomics 15: 405-411, 2018. PMID: 30194081. DOI: 10.21873/cgp.20099
    OpenUrlAbstract/FREE Full Text
  14. ↵
    1. Chen M,
    2. Wang J
    : Initiator caspases in apoptosis signaling pathways. Apoptosis 7: 313-319, 2002. PMID: 12101390.
    OpenUrlCrossRefPubMed
  15. ↵
    1. Yu J,
    2. Zhang L,
    3. Hwang PM,
    4. Kinzler KW,
    5. Vogelstein B
    : PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7: 673-682, 2001. PMID: 11463391.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Yang SY,
    2. Sales KM,
    3. Fuller B,
    4. Seifalian AM,
    5. Winslet MC
    : Apoptosis and colorectal cancer: implications for therapy. Trends Mol Med 15: 225-233, 2009. PMID: 19362056. DOI: 10.1016/j.molmed.2009.03.003
    OpenUrlCrossRefPubMed
  17. ↵
    1. Li H,
    2. Zhu H,
    3. Xu CJ,
    4. Yuan J
    : Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501, 1998. PMID: 9727492.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Kuwana T,
    2. Smith JJ,
    3. Muzio M,
    4. Dixit V,
    5. Newmeyer DD,
    6. Kornbluth S
    : Apoptosis induction by caspase-8 is amplified through the mitochondrial release of cytochrome c. J Biol Chem 273: 16589-16594, 1998. PMID: 9632731.
    OpenUrlAbstract/FREE Full Text
  19. ↵
    1. Juo P,
    2. Kuo CJ,
    3. Yuan J,
    4. Blenis J
    : Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade. Curr Biol 8: 1001-1008, 1998. PMID: 9740801.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Li C,
    2. Zhao H,
    3. Hu Z,
    4. Liu Z,
    5. Wang LE,
    6. Gershenwald JE,
    7. Prieto VG,
    8. Lee JE,
    9. Duvic M,
    10. Grimm EA,
    11. Wei Q
    : Genetic variants and haplotypes of the caspase-8 and caspase-10 genes contribute to susceptibility to cutaneous melanoma. Hum Mutat 29: 1443-1451, 2008. PMID: 18563783. DOI: 10.1002/humu.20803
    OpenUrlCrossRefPubMed
  21. ↵
    1. Rihani A,
    2. De Wilde B,
    3. Zeka F,
    4. Laureys G,
    5. Francotte N,
    6. Tonini GP,
    7. Coco S,
    8. Versteeg R,
    9. Noguera R,
    10. Schulte JH,
    11. Eggert A,
    12. Stallings RL,
    13. Speleman F,
    14. Vandesompele J,
    15. Van Maerken T
    : CASP8 SNP D302H (rs1045485) is associated with worse survival in MYCN-amplified neuroblastoma patients. PLoS One 9: e114696, 2014. PMID: 25502557. DOI: 10.1371/journal.pone. 0114696
    OpenUrl
  22. ↵
    1. Zhang Y,
    2. Li W,
    3. Hong Y,
    4. Wu G,
    5. He K,
    6. Liu D
    : A systematic analysis of the association studies between CASP8 D302H polymorphisms and breast cancer risk. J Genet 96: 283-289, 2017. PMID: 28674227.
    OpenUrl
  23. ↵
    1. de Martino M,
    2. Haitel A,
    3. Schatzl G,
    4. Klingler HC,
    5. Klatte T
    : The CASP8 -652 6N insertion/deletion promoter polymorphism is associated with renal cell carcinoma risk and metastasis. J Urol 190: 717-722, 2013. PMID: 23313206. DOI: 10.1016/j.juro.2013.01.008
    OpenUrlPubMed
  24. ↵
    1. Hashemi M,
    2. Eskandari-Nasab E,
    3. Fazaeli A,
    4. Rezaei H,
    5. Mashhadi MA,
    6. Arbabi F,
    7. Taheri M
    : Bi-directional PCR allele-specific amplification (bi-PASA) for detection of caspase-8 -652 6N ins/del promoter polymorphism (rs3834129) in breast cancer. Gene 505: 176-179, 2012. PMID: 22659694. DOI: 10.1016/j.gene.2012.05.043
    OpenUrl
  25. ↵
    1. Srivastava K,
    2. Srivastava A,
    3. Mittal B
    : Caspase-8 polymorphisms and risk of gallbladder cancer in a northern Indian population. Mol Carcinog 49: 684-692, 2010. PMID: 20564345. DOI: 10.1002/mc.20641
    OpenUrlPubMed
  26. ↵
    1. Yueh TC,
    2. Wu CN,
    3. Hung YW,
    4. Chang WS,
    5. Fu CK,
    6. Pei JS,
    7. Wu MH,
    8. Lai YL,
    9. Lee YM,
    10. Yen ST,
    11. Li HT,
    12. Tsai CW,
    13. Bau DT
    : The Contribution of MMP-7 genotypes to colorectal cancer susceptibility in Taiwan. Cancer Genomics Proteomics 15: 207-212, 2018. PMID: 29695403. DOI: 10.21873/cgp.20079
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Kruidering M,
    2. Evan GI
    : Caspase-8 in apoptosis: the beginning of “the end”? IUBMB Life 50: 85-90, 2000. PMID: 11185963. DOI: 10.1080/713803693
    OpenUrlCrossRefPubMed
  28. ↵
    1. Ghavami S,
    2. Hashemi M,
    3. Ande SR,
    4. Yeganeh B,
    5. Xiao W,
    6. Eshraghi M,
    7. Bus CJ,
    8. Kadkhoda K,
    9. Wiechec E,
    10. Halayko AJ,
    11. Los M
    : Apoptosis and cancer: mutations within caspase genes. J Med Genet 46: 497-510, 2009. PMID: 19505876. DOI: 10.1136/jmg.2009.066944
    OpenUrlAbstract/FREE Full Text
  29. ↵
    1. Li J,
    2. Yuan J
    : Caspases in apoptosis and beyond. Oncogene 27: 6194-6206, 2008. PMID: 18931687. DOI: 10.1038/onc.2008.297
    OpenUrlCrossRefPubMed
  30. ↵
    1. Ashkenazi A
    : Targeting the extrinsic apoptotic pathway in cancer: lessons learned and future directions. J Clin Invest 125: 487-489, 2015. PMID: 25642709. DOI: 10.1172/JCI80420
    OpenUrlCrossRefPubMed
  31. ↵
    1. Sun T,
    2. Gao Y,
    3. Tan W,
    4. Ma S,
    5. Shi Y,
    6. Yao J,
    7. Guo Y,
    8. Yang M,
    9. Zhang X,
    10. Zhang Q,
    11. Zeng C,
    12. Lin D
    : A six-nucleotide insertion-deletion polymorphism in the CASP8 promoter is associated with susceptibility to multiple cancers. Nat Genet 39: 605-613, 2007. PMID: 17450141. DOI: 10.1038/ng2030
    OpenUrlCrossRefPubMed
  32. ↵
    1. Pardini B,
    2. Verderio P,
    3. Pizzamiglio S,
    4. Nici C,
    5. Maiorana MV,
    6. Naccarati A,
    7. Vodickova L,
    8. Vymetalkova V,
    9. Veneroni S,
    10. Daidone MG,
    11. Ravagnani F,
    12. Bianchi T,
    13. Bujanda L,
    14. Carracedo A,
    15. Castells A,
    16. Ruiz-Ponte C,
    17. Morreau H,
    18. Howarth K,
    19. Jones A,
    20. Castellvi-Bel S,
    21. Li L,
    22. Tomlinson I,
    23. Van Wezel T,
    24. Vodicka P,
    25. Radice P,
    26. Peterlongo P,
    27. Consortium E
    : Association between CASP8 - 652 6N del polymorphism (rs3834129) and colorectal cancer risk: results from a multi-centric study. PLoS One 9: e85538, 2014. PMID: 24465592. DOI: 10.1371/journal.pone.0085538
    OpenUrl
  33. ↵
    1. Xiao MS,
    2. Chang L,
    3. Li WL,
    4. Du YS,
    5. Pan Y,
    6. Zhang DF,
    7. Wen Y,
    8. Luo J,
    9. Li XY,
    10. Yao YG
    : Genetic polymorphisms of the CASP8 gene promoter may not be associated with colorectal cancer in Han Chinese from southwest China. PLoS One 8: e67577, 2013. PMID: 23844036. DOI: 10.1371/journal. pone.0067577
    OpenUrl
  34. ↵
    1. Ying Y,
    2. Xu J,
    3. Qi Y,
    4. Zhang M,
    5. Yang Y
    : CASP8 rs3834129 (-652 6N insertion/deletion) polymorphism and colorectal cancer susceptibility: an updated meta-analysis. J Cancer 9: 4166-4171, 2018. PMID: 30519316. DOI: 10.7150/jca.27110
    OpenUrl
  35. ↵
    1. Terry P,
    2. Ekbom A,
    3. Lichtenstein P,
    4. Feychting M,
    5. Wolk A
    : Long-term tobacco smoking and colorectal cancer in a prospective cohort study. Int J Cancer 91: 585-587, 2001. PMID: 11251986.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 39 (6)
Anticancer Research
Vol. 39, Issue 6
June 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Contribution of Caspase-8 Genotypes to Colorectal Cancer Risk in Taiwan
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
15 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Contribution of Caspase-8 Genotypes to Colorectal Cancer Risk in Taiwan
MING-HSIEN WU, YI-WEN HUNG, CHI-LI GONG, CHI-CHANG CHAO, TE-CHENG YUEH, SHOU-CHENG WANG, YI-LIANG LAI, SHIH-WEI HSU, CHUN-KAI FU, YUN-CHI WANG, TAO-WEI KE, WEN-SHIN CHANG, CHIA-WEN TSAI, DA-TIAN BAU
Anticancer Research Jun 2019, 39 (6) 2791-2797; DOI: 10.21873/anticanres.13406

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Contribution of Caspase-8 Genotypes to Colorectal Cancer Risk in Taiwan
MING-HSIEN WU, YI-WEN HUNG, CHI-LI GONG, CHI-CHANG CHAO, TE-CHENG YUEH, SHOU-CHENG WANG, YI-LIANG LAI, SHIH-WEI HSU, CHUN-KAI FU, YUN-CHI WANG, TAO-WEI KE, WEN-SHIN CHANG, CHIA-WEN TSAI, DA-TIAN BAU
Anticancer Research Jun 2019, 39 (6) 2791-2797; DOI: 10.21873/anticanres.13406
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Contribution of Matrix Metalloproteinase-1 Genotypes to Colorectal Cancer in Taiwan
  • Association of Adiponectin Genotypes With Colorectal Cancer Susceptibility in Taiwan
  • Significant Association Between the MiR146a Genotypes and Susceptibility to Childhood Acute Lymphoblastic Leukemia in Taiwan
  • The Joint Effect of Interleukin-12B rs3212227 Genotype and Behavioral Factors on Oral Cancer Risk in Taiwanese
  • Association of Caspase-8 Genotypes With Bladder Cancer Risk
  • Google Scholar

More in this TOC Section

  • 5-Azacytidine (5-aza) Induces p53-associated Cell Death Through Inhibition of DNA Methyltransferase Activity in Hep3B and HT-29 Cells
  • Prognostic Value of WNT1, NOTCH1, PDGFRβ, and CXCR4 in Oral Squamous Cell Carcinoma
  • Hypoxia-adapted Multiple Myeloma Stem Cells Resist γδ-T-Cell-mediated Killing by Modulating the Mevalonate Pathway
Show more Experimental Studies

Similar Articles

Keywords

  • case–control study
  • caspase-8
  • colorectal cancer
  • Genotype
  • polymorphism
  • Taiwan
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire